Clinical Trials Logo

Clinical Trial Summary

This is a multicentric, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to allogeneic stem cell transplantation (SCT) in patients with haematological malignancies.

The aim is to demonstrate a clinical benefit compared with historical data on intravenous busulfan (BusulfexTM, BusilvexTM), the only drug so far registered in the indication conditioning before allogeneic stem cell transplantation.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT00598624
Study type Interventional
Source IRCCS San Raffaele
Contact Luciano LC Callegaro, Monitor
Phone +390226433903
Status Unknown status
Phase Phase 2
Start date September 2005
Completion date December 2010

See also
  Status Clinical Trial Phase
Recruiting NCT02530463 - Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Terminated NCT02469415 - Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Phase 2
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT00987480 - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Phase 2
Recruiting NCT02385110 - Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Phase 2
Recruiting NCT02910752 - CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT02668653 - Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) Phase 3
Withdrawn NCT02829840 - Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Recruiting NCT02458014 - Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease Phase 2
Active, not recruiting NCT02409121 - A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers N/A
Unknown status NCT02360930 - Vincristine PK and PD in the AYA Population Compared to Younger Children N/A
Active, not recruiting NCT01682226 - Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies Phase 2
Completed NCT01057290 - Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia N/A
Completed NCT01410344 - Allogeneic Transplant in HIV Patients (BMT CTN 0903) Phase 2
Completed NCT01438138 - Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia N/A
Completed NCT01357655 - Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) Phase 2
Completed NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Completed NCT01431664 - AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia Phase 1